Cargando…
PCR Array Technology in Biopsy Samples Identifies Up-Regulated mTOR Pathway Genes as Potential Rejection Biomarkers After Kidney Transplantation
Background: Antibody-mediated rejection (AMR) is the major cause of kidney transplant rejection. The donor-specific human leukocyte antigen (HLA) antibody (DSA) response to a renal allograft is not fully understood yet. mTOR complex has been described in the accommodation or rejection of transplants...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7927668/ https://www.ncbi.nlm.nih.gov/pubmed/33681239 http://dx.doi.org/10.3389/fmed.2021.547849 |
_version_ | 1783659728460578816 |
---|---|
author | Legaz, Isabel Bernardo, María Victoria Alfaro, Rafael Martínez-Banaclocha, Helios Galián, Jose Antonio Jimenez-Coll, Victor Boix, Francisco Mrowiec, Anna Salmeron, Diego Botella, Carmen Parrado, Antonio Moya-Quiles, María Rosa Minguela, Alfredo Llorente, Santiago de la Peña-Moral, Jesús Muro, Manuel |
author_facet | Legaz, Isabel Bernardo, María Victoria Alfaro, Rafael Martínez-Banaclocha, Helios Galián, Jose Antonio Jimenez-Coll, Victor Boix, Francisco Mrowiec, Anna Salmeron, Diego Botella, Carmen Parrado, Antonio Moya-Quiles, María Rosa Minguela, Alfredo Llorente, Santiago de la Peña-Moral, Jesús Muro, Manuel |
author_sort | Legaz, Isabel |
collection | PubMed |
description | Background: Antibody-mediated rejection (AMR) is the major cause of kidney transplant rejection. The donor-specific human leukocyte antigen (HLA) antibody (DSA) response to a renal allograft is not fully understood yet. mTOR complex has been described in the accommodation or rejection of transplants and integrates responses from a wide variety of signals. The aim of this study was to analyze the expression of the mTOR pathway genes in a large cohort of kidney transplant patients to determine its possible influence on the transplant outcome. Methods: A total of 269 kidney transplant patients monitored for DSA were studied. The patients were divided into two groups, one with recipients that had transplant rejection (+DSA/+AMR) and a second group of recipients without rejection (+DSA/–AMR and –DSA/–AMR, controls). Total RNA was extracted from kidney biopsies and reverse transcribed to cDNA. Human mTOR-PCR array technology was used to determine the expression of 84 mTOR pathway genes. STRING and REVIGO software were used to simulate gene to gene interaction and to assign a molecular function. Results: The studied groups showed a different expression of the mTOR pathway related genes. Recipients that had transplant rejection showed an over-expressed transcript (≥5-fold) of AKT1S1, DDIT4, EIF4E, HRAS, IGF1, INS, IRS1, PIK3CD, PIK3CG, PRKAG3, PRKCB (>12-fold), PRKCG, RPS6KA2, TELO2, ULK1, and VEGFC, compared with patients that did not have rejection. AKT1S1 transcripts were more expressed in +DSA/–AMR biopsies compared with +DSA/+AMR. The main molecular functions of up-regulated gene products were phosphotransferase activity, insulin-like grown factor receptor and ribonucleoside phosphate binding. The group of patients with transplant rejection also showed an under-expressed transcript (≥5-fold) of VEGFA (>15-fold), RPS6, and RHOA compared with the group without rejection. The molecular function of down-regulated gene products such as protein kinase activity and carbohydrate derivative binding proteins was also analyzed. Conclusions: We have found a higher number of over-expressed mTOR pathway genes than under-expressed ones in biopsies from rejected kidney transplants (+DSA/+AMR) with respect to controls. In addition to this, the molecular function of both types of transcripts (over/under expressed) is different. Therefore, further studies are needed to determine if variations in gene expression profiles can act as predictors of graft loss, and a better understanding of the mechanisms of action of the involved proteins would be necessary. |
format | Online Article Text |
id | pubmed-7927668 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79276682021-03-04 PCR Array Technology in Biopsy Samples Identifies Up-Regulated mTOR Pathway Genes as Potential Rejection Biomarkers After Kidney Transplantation Legaz, Isabel Bernardo, María Victoria Alfaro, Rafael Martínez-Banaclocha, Helios Galián, Jose Antonio Jimenez-Coll, Victor Boix, Francisco Mrowiec, Anna Salmeron, Diego Botella, Carmen Parrado, Antonio Moya-Quiles, María Rosa Minguela, Alfredo Llorente, Santiago de la Peña-Moral, Jesús Muro, Manuel Front Med (Lausanne) Medicine Background: Antibody-mediated rejection (AMR) is the major cause of kidney transplant rejection. The donor-specific human leukocyte antigen (HLA) antibody (DSA) response to a renal allograft is not fully understood yet. mTOR complex has been described in the accommodation or rejection of transplants and integrates responses from a wide variety of signals. The aim of this study was to analyze the expression of the mTOR pathway genes in a large cohort of kidney transplant patients to determine its possible influence on the transplant outcome. Methods: A total of 269 kidney transplant patients monitored for DSA were studied. The patients were divided into two groups, one with recipients that had transplant rejection (+DSA/+AMR) and a second group of recipients without rejection (+DSA/–AMR and –DSA/–AMR, controls). Total RNA was extracted from kidney biopsies and reverse transcribed to cDNA. Human mTOR-PCR array technology was used to determine the expression of 84 mTOR pathway genes. STRING and REVIGO software were used to simulate gene to gene interaction and to assign a molecular function. Results: The studied groups showed a different expression of the mTOR pathway related genes. Recipients that had transplant rejection showed an over-expressed transcript (≥5-fold) of AKT1S1, DDIT4, EIF4E, HRAS, IGF1, INS, IRS1, PIK3CD, PIK3CG, PRKAG3, PRKCB (>12-fold), PRKCG, RPS6KA2, TELO2, ULK1, and VEGFC, compared with patients that did not have rejection. AKT1S1 transcripts were more expressed in +DSA/–AMR biopsies compared with +DSA/+AMR. The main molecular functions of up-regulated gene products were phosphotransferase activity, insulin-like grown factor receptor and ribonucleoside phosphate binding. The group of patients with transplant rejection also showed an under-expressed transcript (≥5-fold) of VEGFA (>15-fold), RPS6, and RHOA compared with the group without rejection. The molecular function of down-regulated gene products such as protein kinase activity and carbohydrate derivative binding proteins was also analyzed. Conclusions: We have found a higher number of over-expressed mTOR pathway genes than under-expressed ones in biopsies from rejected kidney transplants (+DSA/+AMR) with respect to controls. In addition to this, the molecular function of both types of transcripts (over/under expressed) is different. Therefore, further studies are needed to determine if variations in gene expression profiles can act as predictors of graft loss, and a better understanding of the mechanisms of action of the involved proteins would be necessary. Frontiers Media S.A. 2021-02-17 /pmc/articles/PMC7927668/ /pubmed/33681239 http://dx.doi.org/10.3389/fmed.2021.547849 Text en Copyright © 2021 Legaz, Bernardo, Alfaro, Martínez-Banaclocha, Galián, Jimenez-Coll, Boix, Mrowiec, Salmeron, Botella, Parrado, Moya-Quiles, Minguela, Llorente, Peña-Moral and Muro. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Medicine Legaz, Isabel Bernardo, María Victoria Alfaro, Rafael Martínez-Banaclocha, Helios Galián, Jose Antonio Jimenez-Coll, Victor Boix, Francisco Mrowiec, Anna Salmeron, Diego Botella, Carmen Parrado, Antonio Moya-Quiles, María Rosa Minguela, Alfredo Llorente, Santiago de la Peña-Moral, Jesús Muro, Manuel PCR Array Technology in Biopsy Samples Identifies Up-Regulated mTOR Pathway Genes as Potential Rejection Biomarkers After Kidney Transplantation |
title | PCR Array Technology in Biopsy Samples Identifies Up-Regulated mTOR Pathway Genes as Potential Rejection Biomarkers After Kidney Transplantation |
title_full | PCR Array Technology in Biopsy Samples Identifies Up-Regulated mTOR Pathway Genes as Potential Rejection Biomarkers After Kidney Transplantation |
title_fullStr | PCR Array Technology in Biopsy Samples Identifies Up-Regulated mTOR Pathway Genes as Potential Rejection Biomarkers After Kidney Transplantation |
title_full_unstemmed | PCR Array Technology in Biopsy Samples Identifies Up-Regulated mTOR Pathway Genes as Potential Rejection Biomarkers After Kidney Transplantation |
title_short | PCR Array Technology in Biopsy Samples Identifies Up-Regulated mTOR Pathway Genes as Potential Rejection Biomarkers After Kidney Transplantation |
title_sort | pcr array technology in biopsy samples identifies up-regulated mtor pathway genes as potential rejection biomarkers after kidney transplantation |
topic | Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7927668/ https://www.ncbi.nlm.nih.gov/pubmed/33681239 http://dx.doi.org/10.3389/fmed.2021.547849 |
work_keys_str_mv | AT legazisabel pcrarraytechnologyinbiopsysamplesidentifiesupregulatedmtorpathwaygenesaspotentialrejectionbiomarkersafterkidneytransplantation AT bernardomariavictoria pcrarraytechnologyinbiopsysamplesidentifiesupregulatedmtorpathwaygenesaspotentialrejectionbiomarkersafterkidneytransplantation AT alfarorafael pcrarraytechnologyinbiopsysamplesidentifiesupregulatedmtorpathwaygenesaspotentialrejectionbiomarkersafterkidneytransplantation AT martinezbanaclochahelios pcrarraytechnologyinbiopsysamplesidentifiesupregulatedmtorpathwaygenesaspotentialrejectionbiomarkersafterkidneytransplantation AT galianjoseantonio pcrarraytechnologyinbiopsysamplesidentifiesupregulatedmtorpathwaygenesaspotentialrejectionbiomarkersafterkidneytransplantation AT jimenezcollvictor pcrarraytechnologyinbiopsysamplesidentifiesupregulatedmtorpathwaygenesaspotentialrejectionbiomarkersafterkidneytransplantation AT boixfrancisco pcrarraytechnologyinbiopsysamplesidentifiesupregulatedmtorpathwaygenesaspotentialrejectionbiomarkersafterkidneytransplantation AT mrowiecanna pcrarraytechnologyinbiopsysamplesidentifiesupregulatedmtorpathwaygenesaspotentialrejectionbiomarkersafterkidneytransplantation AT salmerondiego pcrarraytechnologyinbiopsysamplesidentifiesupregulatedmtorpathwaygenesaspotentialrejectionbiomarkersafterkidneytransplantation AT botellacarmen pcrarraytechnologyinbiopsysamplesidentifiesupregulatedmtorpathwaygenesaspotentialrejectionbiomarkersafterkidneytransplantation AT parradoantonio pcrarraytechnologyinbiopsysamplesidentifiesupregulatedmtorpathwaygenesaspotentialrejectionbiomarkersafterkidneytransplantation AT moyaquilesmariarosa pcrarraytechnologyinbiopsysamplesidentifiesupregulatedmtorpathwaygenesaspotentialrejectionbiomarkersafterkidneytransplantation AT minguelaalfredo pcrarraytechnologyinbiopsysamplesidentifiesupregulatedmtorpathwaygenesaspotentialrejectionbiomarkersafterkidneytransplantation AT llorentesantiago pcrarraytechnologyinbiopsysamplesidentifiesupregulatedmtorpathwaygenesaspotentialrejectionbiomarkersafterkidneytransplantation AT delapenamoraljesus pcrarraytechnologyinbiopsysamplesidentifiesupregulatedmtorpathwaygenesaspotentialrejectionbiomarkersafterkidneytransplantation AT muromanuel pcrarraytechnologyinbiopsysamplesidentifiesupregulatedmtorpathwaygenesaspotentialrejectionbiomarkersafterkidneytransplantation |